

30 March 2022

To: Recipients of MR14-Ed1

From: Jennifer K. Adams, MT(ASCP), MSHA
Vice President, Standards and Quality

Subject: Correction

This notice is intended to inform users of a correction made to CLSI document MR14, *Piperacillin-Tazobactam Breakpoints for Enterobacterales*, 1st ed. The correction is described below and shown as highlighted text in the table excerpt.

Table 5. Summary of Studies Investigating Piperacillin-Tazobactam PK and PD Data

The dosage listed with an infusion time of three hours and an MIC with $\geq 90\%$ PTA of $\leq 16 \mu\text{g/mL}$ is listed incorrectly as 4.5 g every 8 h. The dosage has been corrected to 4.5 g every 6 h.

Table 5. Summary of Studies Investigating Piperacillin-Tazobactam PK and PD Data

Dosage	Infusion Time	MIC With $\geq 90\%$ PTA ^a
3.375 g every 6 h	30 min	$\leq 8 \mu\text{g/mL}$ ¹⁰⁻¹²
4.5 g every 6 h	30 min	$\leq 8 \mu\text{g/mL}$ ¹²⁻¹⁵
3.375 g every 8 h	4 h	$\leq 8 \mu\text{g/mL}$ ¹⁴⁻¹⁷
4.5 g every 8 h	4 h	$\leq 8 \mu\text{g/mL}$ ¹²⁻¹⁵
4.5 g every 8 h	4 h	$\leq 16 \mu\text{g/mL}$ ^{12,14,17,18}
4.5 g every 6 h	3 h	$\leq 16 \mu\text{g/mL}$ ^{12,13,18,19}

Abbreviations: h, hour; MIC, minimal inhibitory concentration; min, minute; PD, pharmacodynamic; PK, pharmacokinetic; PTA, probability of target attainment.

^a Using a $50\% f_{T > MIC}$; no study demonstrated that an MIC $> 16 \mu\text{g/mL}$ was achievable with normal renal function, regardless of methodology, dosage, or infusion time.

If you require any additional clarification regarding these corrections, please contact CLSI Customer Service (customerservice@clsi.org).

We appreciate your commitment to CLSI and regret any inconvenience.